Neurofibromatoses Type II - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Neurofibromatoses Type II - Pipeline Review, H2 2016

Neurofibromatoses Type II - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Neurofibromatoses Type II - Pipeline Review, H2 2016
Published Oct 29, 2016
53 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses Type II (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type II Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively for Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively for Neurofibromatoses Type II.

Neurofibromatoses Type II (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neurofibromatoses Type II (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neurofibromatoses Type II (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the

  
Source:
Document ID
GMDHC8603IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Neurofibromatoses Type II Overview61
Therapeutics Development72
  Pipeline Products for Neurofibromatoses Type II Overview71
  Pipeline Products for Neurofibromatoses Type II Comparative Analysis81
Neurofibromatoses Type II Therapeutics under Development by Companies91
Neurofibromatoses Type II Therapeutics under Investigation by Universities/Institutes101
Neurofibromatoses Type II Pipeline Products Glance112
  Clinical Stage Products111
  Early Stage Products121
Neurofibromatoses Type II Products under Development by Companies131
Neurofibromatoses Type II Products under Investigation by Universities/Institutes141
Neurofibromatoses Type II Companies Involved in Therapeutics Development155
  Arno Therapeutics, Inc.151
  Betta Pharmaceuticals Co. Ltd.161
  Lixte Biotechnology Holdings, Inc.171
  Novartis AG181
  Plex Pharmaceuticals, Inc.191
Neurofibromatoses Type II Therapeutics Assessment209
  Assessment by Monotherapy Products201
  Assessment by Target212
  Assessment by Mechanism of Action232
  Assessment by Route of Administration252
  Assessment by Molecule Type272
Drug Profiles2921
  AR-42 Drug Profile292
  everolimus Drug Profile3112
  FRAX-597 Drug Profile431
  icotinib hydrochloride Drug Profile442
  LB-201 Drug Profile461
  LB-205 Drug Profile471
  Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 Drug Profile481
  Vaccine to Target VEGFR1 and VEGFR2 for Oncology Drug Profile491
Neurofibromatoses Type II Dormant Projects501
Neurofibromatoses Type II Product Development Milestones511
  Featured News &Press Releases511
    May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42511
Appendix522
  Methodology521
  Coverage521
  Secondary Research521
  Primary Research521
  Expert Panel Validation521
  Contact Us521
  Disclaimer531

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Neurofibromatoses Type II - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neurofibromatoses-Type-II-Pipeline-Review-H2-2016-2088-16719>
  
APA:
Global Markets Direct - Market Research. (2016). Neurofibromatoses Type II - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neurofibromatoses-Type-II-Pipeline-Review-H2-2016-2088-16719>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.